Adam Jacob Schoenfeld

Adam Jacob Schoenfeld, MD, serves as an Assistant Attending physician in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC), specializing in Thoracic Oncology within the Solid Tumor Oncology Division. His clinical and research focus centers on advancing immunotherapeutic interventions for solid malignancies, particularly non-small cell lung cancer.

Dr. Schoenfeld's research program emphasizes lung cancer immunotherapy, engineered T-cell therapies, and innovative clinical trial design. He actively develops transgenic TCR approaches targeting KRAS mutations and investigates tumor-infiltrating lymphocyte (TIL) platforms, bridging translational science with patient-centered care delivery through telehealth integration.

His 2025 publication portfolio demonstrates concentrated expertise in cellular therapy innovation for solid tumors, spanning phase I clinical trials, comprehensive reviews, and patient experience studies. Key thematic areas include TCR engineering for HLA-restricted mutations, next-generation TIL manufacturing, and digital health solutions for immunotherapy management across Journal of Clinical Oncology and Cytotherapy.

Scientific Awards: No specific honors or fellowships are documented in the source materials.

Dr. Schoenfeld maintains extensive collaborative networks at MSKCC, evidenced by co-authorship with prominent researchers including Riely (38 collaborations), Ladanyi (36), and Rizvi (27). His work leverages institutional resources within MSKCC's Solid Tumor Oncology infrastructure, though grant details remain unspecified.

He operates within MSKCC's Thoracic Oncology service and Solid Tumor Oncology Division, directing research efforts toward novel immunotherapeutic strategies for advanced lung cancers while integrating telehealth innovations into patient care frameworks.